Reply
Yu Sun, Shu‐Yong Lin – 1 February 2018
Role of monocyte chemoattractant protein‐1 in liver fibrosis with transient myeloproliferative disorder in down syndrome
Kenichiro Kobayashi, Takako Yoshioka, Jun Miyauchi, Atsuko Nakazawa, Nobutaka Kiyokawa, Toshiro Maihara, Ikuya Usami – 1 February 2018 – Liver fibrosis is a common complication associated with transient myeloproliferative disorder (TMD) in Down syndrome (DS). The exact molecular pathogenesis that regulates disease progression is largely unknown. We recently found serum and/or urinary monocyte chemoattractant protein‐1 (MCP‐1) as a novel biomarker of liver fibrosis.
Reply
Qiang Liu, Laura Buccini, Daniele Pezzati, Ahmed Hassan, Teresa Diago Uso, Charles Miller, Cristiano Quintini – 1 February 2018
Correction
31 January 2018
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
- Read more about Clinical studies investigating the effect of vitamin E therapy in patients with NASH
Sebastian Larion, Sandeep Khurana – 31 January 2018
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
Meera Ramanathan, Anil Seetharam – 31 January 2018
Intra‐arterial locoregional therapy in the management of hepatocellular carcinoma
Meera Ramanathan, Anil Seetharam – 31 January 2018
Review of hepatobiliary contrast agents: Current applications and challenges
Alex Frydrychowicz – 31 January 2018
Clinical studies investigating the effect of vitamin E therapy in patients with NASH
- Read more about Clinical studies investigating the effect of vitamin E therapy in patients with NASH
Sebastian Larion, Sandeep Khurana – 31 January 2018
Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial
Norman L. Sussman, James H. Kelly – 31 January 2018